Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Exploring strategic collaborations and key considerations arising from down-round financings, bridge rounds, and other restructuring scenarios.

Virtual Webinar

Financing and restructuring strategies for private biotech companies

Strategic Options in a Downturn for Private Companies

Covering product development and confidentiality, and their evolving impact on business strategy.

IP and patent strategies for biotech companies in difficult markets

Patent Strategy in Challenging Times

Seeing how public biotechs manage a tough financing environment – including different approaches to financing on new data; trends in PIPEs, RDs, and CMPOs; strategic burn and development decisions; big pharma trends; changes in reverse mergers; royalty financing news; use of ATMs.

Seeing how public biotechs manage a tough financing environment

Keeping the Lights On: Business Perspectives on Raising Capital for Public Life Science Companies

A webinar series helping biotech and life sciences companies navigate today's volatile markets and prepare for what's next.

In this rapidly evolving market, biotech and life sciences leaders are under growing pressure to make complex decisions during times of uncertainty. Tune in for What's Next: Life Sciences at a Crossroads, our webinar series that brings together legal advisors, industry voices, and capital market leaders to explore timely challenges. Designed to be short, sharp, and strategic, each session will equip you with actionable takeaways — from financing and corporate governance to IP strategy, cross-border risk, and regulatory developments.

Goodwin

What's Next: Life Sciences at a Crossroads

main

Life Sciences Webinar Series

A webinar series featuring legal advisors helping biotech and life sciences companies navigate today’s volatile markets and prepare for what’s next.

What’s Next: Life Sciences at a Crossroads

Upcoming Webinars

Past Webinars

September 30: Navigating a Changing FDA: Regulatory and Financing Insights

June 24: Keeping The Lights On: Business Perspectives on Raising Capital for Public Life Sciences Companies

June 11: Patent Strategy in Challenging Times

June 3: Strategic Options in a Downturn for Private Companies

May 20: The Future of Biotech Regulation

May 13: Beyond the IPO: Financing Alternatives for Public Companies in a Tough Market

Contact Us

Our Life Sciences Practice

New Directions Audio Series

Related Content

Noelle C. Dubiansky

Felipe M. Heiderich

Catherine McCarty

Jacqueline Mercier

Elizabeth Mulkey

Edwin M. O'Connor

Joshua Rottner

Matt Wetzel

Sam Zucker

Life Sciences